Effects of nitrendipine on plasma levels of insulin and glucose in patients with essential hypertension

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 3, 1997, Pages 180-186

  Ricciardelli, Bruno ^a   Argenziano, Luigi ^a   Morisco, Carmine ^b   Monti, Francesco ^b   Barbato, Emanuele ^a   Trimarco, Bruno ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

calcium antagonists; glucose tolerance; hypertension; therapy

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; GLUCOSE; INSULIN; NITRENDIPINE; PLACEBO;

ADULT; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SITTING; STANDING;

EID: 0030994805     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80013-6     Document Type: Article

References (13)

1. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. NEJM. 1989;321:868-873.
2. Ferranini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. NEJM. 1987;317:350-357.
3. Reaven GM. Role of insulin resistance in human disease. Banting lecture 1988. Diabetes. 1988;37:1595-1607.
4. DeFronzo RA, Ferranini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
5. Landsberg L. Insulin and hypertension: Lesson from obesity. NEJM. 1987;317:378-379.
6. Hansson L, Dahlof B. What are we really achieving with long-term antihypertensive drug therapy? In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press; 1990:2131-2141.
7. WHO/ISH Guidelines Committee. Prevention of hypertension and associated cardiovascular disease: A 1991 statement. Clin Exp Hypertens. 1992;A14:333-341.
8. Nestler JE, Clore JN, Blackard WG. Dehydroepiandrosterone: The "missing link" between hyperinsulinemia and atherosclerosis? FASEB J. 1992;6:3073-3075.
9. Nafziger AN, Herrington DM, Bush TL. Dehydroepiandrosterone and dehydroepiandrosterone sulfate: Their relation to cardiovascular disease. Epidemiol Rev. 1991;13:267-293.
10. Beer NA, Jakubowicz DJ, Beer RM, Nestler JE. The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab. 1993; 76:1464-1469.
11. Baron AD, Brechtel G, Wallace P, Edelman SV, Rates and tissue sites of non-insulin and insulin-mediated glucose uptake in humans. Am J Physiol. 1988;255:E769-E774.
12. Draznin B, Sussman KE, Eckel RH, et al. Possible role of cytosolic free calcium concentration in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest. 1988;82:1848-1852.
13. Draznin B, Sussman KE, Kao M, et al. The existence of an optimal range of cytosolic free calcium for insulin-stimulated glucose transport in rat adipocites. J Biol Chem. 1987; 262:14385-14388.